Menu Search
Equities

Neuland Laboratories Ltd

NEULANDLAB:NSI

Neuland Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)14,904.95
  • Today's Change71.90 / 0.48%
  • Shares traded10.81k
  • 1 Year change+184.78%
  • Beta1.2975
Data delayed at least 15 minutes, as of Nov 22 2024 10:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Neuland Laboratories Ltd grew revenues 30.84% from 11.91bn to 15.59bn while net income improved 83.51% from 1.64bn to 3.00bn.
Gross margin52.14%
Net profit margin18.30%
Operating margin24.24%
Return on assets15.50%
Return on equity22.13%
Return on investment20.03%
More ▼

Cash flow in INRView more

In 2024, Neuland Laboratories Ltd increased its cash reserves by 92.83%, or 421.60m. The company earned 2.61bn from its operations for a Cash Flow Margin of 16.76%. In addition the company used 1.50bn on investing activities and also paid 692.82m in financing cash flows.
Cash flow per share267.84
Price/Cash flow per share55.14
Book value per share1,081.52
Tangible book value per share863.41
More ▼

Balance sheet in INRView more

Neuland Laboratories Ltd has a Debt to Total Capital ratio of 7.28%, a higher figure than the previous year's 5.39%.
Current ratio2.34
Quick ratio1.40
Total debt/total equity0.0785
Total debt/total capital0.0728
More ▼

Growth rates in INR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 40.00% and 83.51%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
Div yield(5 year avg)0.31%
Div growth rate (5 year)63.45%
Payout ratio (TTM)6.42%
EPS growth(5 years)78.07
EPS (TTM) vs
TTM 1 year ago		5.05
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.